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S100A8 and S100A9 proteins that exhibits a ‘soil signal’) is a ligand for Toll-like receptor 4, causing distant melanoma
cells to approach the lung as a ‘seeding’ site. Unknown soil sensors for S100A8/A9may exist, e.g., extracellular matrix
metalloproteinase inducer, neuroplastin, activated leukocyte cell adhesion molecule, and melanoma cell adhesion
molecule. We call these receptor proteins ‘novel S100 soil sensor receptors (novel SSSRs).’ Here we review and sum-
marize a crucial role of the S100A8/A9-novel SSSRs' axis in cancermetastasis. The binding of S100A8/A9 to individual
SSSRs is important in cancer metastasis via upregulations of the epithelial-mesenchymal transition, cellular motility,
and cancer cell invasiveness, plus the formation of an inflammatory immune suppressive environment in metastatic
organ(s). These metastatic cellular events are caused by the SSSR-featured signal transductions we identified that pro-
vide cancer cells a driving force for metastasis. To deprive cancer cells of these metastatic forces, we developed novel
biologics that prevent the interaction of S100A8/A9 with SSSRs, followed by the efficient suppression of S100A8/A9-
mediated lung-tropic metastasis in vivo.Introduction
We have been investigating cancer metastasis mechanisms at the molecu-
lar level, based on the ‘seed and soil’ theory that was first proposed by Paget
et al. in 1989 [1]. The term ‘seed’ represents the dissemination of cancer cells,
and ‘soil’ represents a favorable environment for the cancer cells to grow
within a given organ. Several research groups have examined the lung-
secreted ligand S100A8/A9 (a heterodimer complex of S100A8 and S100A9
proteins), which attracts cancer cells originating from distant organs [3,2].
Lung S100A8/A9 acts as a strong ‘soil signal’ to its receptors in cancer cells,
which act as ‘S100A8/A9-soil signal sensors.’ In addition to the two known
S100A8/A9 receptors, i.e., toll-like receptor 4 (TLR4) [3,2] and receptor for
advanced glycosylation end products (RAGE) [4], we have identified the fol-
lowing novel S100A8/A9 receptors: extracellular matrix metalloproteinase
inducer (EMMPRIN) [5], neuroplastin (NPTN) α and β (NPTNβ compensates
for NPTNα) [7,6], activated leukocyte cell adhesion molecule (ALCAM), and
melanoma cell adhesion molecule (MCAM) [8–10]. We named this group of
receptors the ‘novel S100 soil sensor receptors (SSSRs)’ [12,11].
As do the two previously identified receptors, the newly identified
receptors play a crucial role in cancer metastasis in response toDepartment of Cell Biology, Okayama
nobu), rie-k@okayama-u.ac.jp, (R. Kin
vier Inc. on behalf of Neoplasia PS100A8/A9. This implies that these receptors may be useful candidate
molecular targets to prevent cancer metastasis [12,11]. In this mini-
review, based mainly on our research history, we first describe how
these receptors are identified, and we then discuss their roles in cancer
and signal transduction, and we consider the therapeutic possibilities
when these molecules are targeted.
Identification of SSSRs and Their Functions in Cancer Metastasis
Identification of EMMPRIN and its Paralogs
S100A8/A9 is a heterodimer complex of S100A8 and S100A9 pro-
teins [13] that correspond to 20 of the S100 family proteins (S100A1–
A16, β, G, P and Z) in humans [14]. Among the S100 family proteins,
S100A8/A9 has an interesting trait; it shows markedly high production
and secretion in the lung even when solid cancer is present at a site that
is remote from the lung. Due to a neoplastic feature of cancers as a for-
eign substance, the lung senses the presence of cancer, and cancer-
mediated inflammation develops at that site as a protection mechanism
against cancer since the lung is one of the sensitive tissues that generallyUniversity Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-
oshita), masa-s@md.okayama-u.ac.jp. (M. Sakaguchi).
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sion of S100A8/A9 can be induced by the inflammation, since several
inflammatory cytokines and chemokines stimulate both the production
and the secretion of S100A8/A9, and secreted S100A8/A9 further stim-
ulates these inflammatory soluble factors in a process that leads to the
formation of a feed-forward loop between inflammatory soluble factors
and S100A8/A9, resulting in S100A8/A9-integrated and persistent in-
flammation [15].
We observed that S100A8/A9 secretion in the lung is also stimulated by
cancer-derived exosomes [7]. The lung-secreted S100A8/A9 attracts re-
mote cancer cells to the lung. S100A8/A9 requires its receptor(s) in order
to act on cancer cells. TLR4 and RAGE are representative receptors for
S100A8/A9 [2–4], but S100A8/A9-mediated cancer metastasis is not ex-
plained by only TLR4 and RAGE since many sorts of metastatic cancer
cell lines show poor expressions of these receptors at both the mRNA and
protein levels (unpubl. data).
Our previous research indicated the potential presence of unidentified
receptors for S100A8/A9, since we observed that S100A8/A9-dependent
signals in cells never faded out even in the setting of a functional inhibition
of both TLR4 and RAGE [16]. To identify novel receptors, we performed a
pull-down assay using S100A8/A9 recombinant protein as a bait to pick up
its receptor candidate(s) from protein extracts. In our subsequent liquid
chromatography–tandem mass spectrometry (LC–MS/MS) analysis of the
precipitated proteins with S100A8/A9, we fortunately succeeded in identi-
fying EMMPRIN as a putative S100A8/A9 receptor [5].
EMMPRIN, also known as basigin or CD147, is a glycoprotein that is a
member of the immunoglobulin superfamily (as is RAGE), and EMMPRIN
plays a crucial role in cancer progression via several functions, including
the following: a facilitated secretion of matrix metalloproteinases (MMPs)
[17], enhanced tumor angiogenesis via the induction of vascular endothe-
lial growth factor (VEGF) [19,18], adhesion with extracellular matrixes
[20], and cancer-associated anaerobic glycolysis by regulating the activity
of the membrane monocarboxylate transporters-1 (MCT-1) and MCT-4,
which transport lactic acid [21]. It was demonstrated that cyclophilinA
(CyPA) functions as an EMMPRIN ligand; the interaction of CyPA and
EMMPRIN stimulates cancer proliferation [17]. We revealed that
S100A8/A9 also functions as a ligand of EMMPRIN; their engagement
plays a crucial role in the lung-tropic metastasis of melanoma [5], as
S100A8/A9 was highly induced in the lungs of melanoma-bearing mice.
To force melanoma cells to metastasize by EMMPRIN triggered by
S100A8/A9 or S100A9 binding, tumor necrosis factor (TNF) receptor-
associated factor 2 (TRAF2)-mediated NFκB activation is required; this
is because the cytoplasmic tail of EMMPRIN recruits TRAF2 adaptor
protein in response to S100A8/A9-EMMPRIN interaction [5]. In light
of the interaction of EMMPRIN with S100A8/A9 via its S100A9 side,
we hypothesized that another receptor that can couple with EMMPRIN
and bind with the S100A8 side of the heterodimer might be present.
Such a receptor may be structurally similar to EMMPRIN, and we thus
conducted a homology search on the basis of the amino acid sequence
of the full length of EMMPRIN. However, no hitting of any appreciable
candidates was observed. Faced with this result, we modified the strat-
egy to conduct an individual domain-based search to identify a greater
number of hitting sequences. The results revealed the presence of
NPTN, whose cytoplasmic domain sequence is very similar to that of
EMMPRIN [6] (Figure 1).
NPTN is a member of the immunoglobulin (Ig) superfamily. It has two
isoforms, NPTNα (Np-55) and NPTNβ (Np-65) that contain two and three
extracellular immunoglobulin domains, respectively. NPTNα and NPTNβ
have been reported to play important roles in a number of key neuronal
and synaptic functions because of their abundant expression in the brain
[23,22]. They also exhibited an unusual role in cancer progression: we re-
vealed this role in the context of S100A8/A9-relatedmetastasis [7].We ob-
served that both the NPTNα and NPTNβ isoforms are able to bind with
S100A9. However, due to its additional N-terminal Ig domain, NPTNβ
can interact with S100A8. We also observed that NPTNβ is able to undergo
dimerization with its own NPTNβ, its α-isoform, and EMMPRIN [6].2
In light of the dominant expression of NPTNβ but not NPTNα in cases of
melanoma, it should be noted that either the NPTNβ/NPTNβ homodimer
or the EMMPRIN/NPTNβ heterodimer presents on the surface ofmelanoma
and functions as an S100A8/A9 receptor, leading melanoma cells to lung-
tropic metastasis. The NPTNβ/NPTNβ homodimer may be dominant in
lung cancer, since NPTNβ expression is markedly upregulated in lung can-
cer species in a consistent manner compared to the expression profiling of
EMMPRIN and NPTNα. In the lung cancer context, we reported that the
S100A8/A9-NPTNβ axis plays a critical role in disseminating the progres-
sion of lung cancer in vitro and in vivo. What downstream signal(s) does
the S100A8/A9-NPTNβ axis use as a driving force for cancer progression
in the lung? We observed a key transcription factor, nuclear factor I (NFI)
A/NFIB, which is positively regulatedmostly by TRAF2, but the growth fac-
tor receptor-bound protein 2 (GRB2)-renin-angiotensin system (RAS) path-
way also contributes to the activation of NFIA/NFIB in an orchestrated
manner with TRAF2.
In the case of RAS, we also observed the importance of ERAS and
RASL11A, which are different from KRAS. The well-known KRAS gene
(which is frequently mutated as an active form in lung cancer) was not in-
volved in the identified pathway. The activation of NFIA/NFIB eventually
led to the induction of many cancer-related genes. One of the most interest-
ing genes was SPDEF (SAM pointed-domain containing ETS transcription
factor). When we artificially regulated the expression of the SPDEF gene,
we observed that SPDEF greatly contributed to lung cancer progression
with enhanced anchorage-independent growth and disseminative activi-
ties. Taken together, our data support the notion that the newly identified
NPTNβ signaling pathway that is initiated by cancer cells surrounding ex-
tracellular S100A8/A9 worsens lung cancers toward their disseminating
progression [7].
We used the structural similarity between EMMPRIN and NPTN and
observed that these molecules are in paralog relation. We also identified
another candidate, embigin (EMB) [24] (Figure 2). EMB is a member of
the Ig superfamily that was first observed in embryonic carcinoma cells.
EMB is highly expressed in pancreatic ductal adenocarcinoma (PDAC)
cells and contributes to the development of PDAC. Jung et al. reported
that the overexpression of EMB in PDAC induces upregulations of the
proliferation, migration, and invasion of PDAC cells [25]. The EMB-
mediated enhanced cell motility is associated with the tumor growth
factor beta (TGFβ) pathway-relevant epithelial-mesenchymal transition
(EMT) [25]. In that study, we first expected that like EMMPRIN and
NPTN, EMB must also work as an S100A8/A9 receptor and would con-
tribute to the progression of PDAC. However, contrary to our expecta-
tion, EMB could not bind with S100A8/A9, but it was able to bind
with another cancer-relevant S100 protein, S100A4 (by another name,
metastasis). We therefore eliminated EMB from the group of S100A8/
A9-associated SSSRs.
Regarding the S100A4-EMB axis, we focused on prostate cancer since
EMB showed the highest expression in prostate cancer cells among the can-
cer cell lines thatwe examined, including PDAC cells. An unusual role of the
S100A4-EMB axis in the progression of prostate cancer was observed, and
we identified a key signal pathway that is regulated by EMB upon
S100A4 binding: an identified AMPK/mTORC1/NFκB/MMP9 pathway is
used as a vital oncogenic molecular cascade in prostate cancer cells for
their progression. Our RNA-seq analysis data further showed that EMB is as-
sociated mostly with cancer-related genes [24].
RAGE Paralogs
According to the idea that paralog(s) should also exist for RAGE, we
searched for the presence of RAGE paralogs and identified basal cell ad-
hesion molecule (BCAM), ALCAM, and MCAM [8] (Figure 2). These are
cell adhesion molecules that belong to the Ig superfamily, like RAGE.
Because there was no binding of BCAM to S100A8/A9, we removed
BCAM from the group of SSSRs and decided to focus on ALCAM and
MCAM, which interact with S100A8/A9. We observed that a functional
inhibition of the intrinsic ALCAM (but not of MCAM) in melanoma cells
Figure 1. The domain structures for EMMPRIN, NPTNα, and NPTNβ. EMMPRIN and NPTN belong to the Ig superfamily consisting of extracellular Ig domains, one
transmembrane domain, and a short cytoplasmic domain. NPTN has alternative splicing variants called NPTNα (Np-55) and NPTNβ (Np-65). A homology search showed
very similar amino acids sequences between EMMPRIN and NPTN.
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model, and we therefore paid more attention to MCAM as a key regula-
tor for melanoma metastasis in response to S100A8/A9.
MCAM, which was originally identified as a tumor biomarker of mel-
anoma [27,26], has long been known to be highly involved in the metas-
tasis of not only melanoma but many other types of cancer through the
regulation of cell migration, invasion, angiogenesis, and immune re-
sponse [28–30]. It is not yet known how MCAM provides the driving
force for metastasis upon S100A8/A9 binding to cancer cells, and we
therefore investigated an unidentified MCAM downstream signal. Our
findings demonstrated that the cytoplasmic tail of MCAM recruits a spe-
cific mitogen-activated protein kinase kinase kinase (MAPKKK) named
tumor progression locus 2 (TPL2), resulting in the activation of ERK1/
2 at a significant level. The activated ERK1/2 was observed to lead to
an active form of ETS variant transcription factor 4 (ETV4) and to the3
subsequent induction of matrix metallopeptidase 25 (MMP25) by the
active ETV4, eventually leading to the skin dissemination of melanoma
cells (an event that is required as a prerequisite for remote metastasis)
[9].
Interestingly, the ETV4-target molecule is changed in different cancer
cells. We revealed that the S100A8/A9-MCAM-TPL2-ETV4 axis leads to
an EMT-mediated disseminative progression of breast cancer cells via a
marked induction of zinc finger E-box binding homeobox 1 (ZEB1) tran-
scription factor [10]. That study was the first report of the unveiled
S100A8/A9-MCAM-mediated signal pathways that lead to aggressive me-
tastasis of melanoma and breast cancer cells [10,9].
We summarized how these novel SSSRs are related to various pri-
mary cancers with their tissue (cell) specificity, by using publicly
available data (Figure 3) (GEPIA: http://gepia.cancer-pku.cn/) and
the available scientific reports. They are presented in Table 1:
Figure 2. The presence of paralogs for EMMPRIN (top) and RAGE (bottom).
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first examined the expression levels of the novel SSSRs in several
types of primary cancers through the website database (Figure 3),
and then the data obtained about relevancy between the elevated ex-
pressions of individual novel SSSRs and their corresponding primary
cancer species were further checked through the scientific reports
(Table 1). By reviewing the combined results from Figure 3 and
Table 1, we found that MCAM is upregulated in glioblastoma, hepato-
cellular carcinoma, and melanoma; ALCAM is upregulated in breast
cancer, pancreatic cancer and prostate cancer; EMMPRIN is upregu-
lated in hepatocellular carcinoma, pancreatic cancer, and melanoma.
In light of these data, our findings from recent melanoma studies
(MCAM [35,9,8], EMMPRIN [5]) were consistent with the summa-
rized results (Table 1). In the case of NPTN, no report in pancreatic
cancers was identified, but we observed that NPTN (especially in its
isoform β) is commonly upregulated in lung cancer cells and is asso-
ciated with an increased potential for the cells' metastasis [7].
The expression of the novel SSSRs will elevate further in accord with
the cancer malignancy. We examined two types of melanoma cell lines
(WM-115 and WM-266-4) that were obtained from the same patient:
the WM-115 cells were from the primary tumor in the skin, and the
WM-266-4 cells were from a metastasized area [44]. Our analyses re-
vealed that MCAM was highly upregulated in the WM-266-4 cells com-
pared to the WM-115 cells [9]. This observation was also made in breast
cancer cells [10]. The expression of MCAM is also proportionally ele-
vated with the progression of malignant stages of breast cancer [10].
Collectively, these results suggest that the expression levels of4
individual SSSRs are closely associated with the primary cancer species,
and their expressions can be altered through their malignant
conversion.
Novel Insights Into the Functions of SSSRs in Metastasis
A discussion of potential common pathway(s) among SSSRs is neces-
sary, since the functions of all of the SSSRs are very similar to one another
in the context of metastasis. The presence of similar pathway(s) is very im-
portant tomutually compensate and synergistically enhance individual sig-
nal pathway(s) from SSSRs. Figure 4 (unpubl. data) illustrates our novel
findings regarding which types of MAPK cascade upstream kinases
(MAPKCUKs) interact with each SSSR. Because the signal cascade ‘snow-
balls’ (Figure 4, left panel), analyses of the signal onset are important to de-
termine the signal dimensions. For MAPKCUKs, the MAPKKKs are located
mostly at the very top of the receptor signal cascades. We thus investigated
the potential recruitment of MAPKKKs to SSSRs.
A similar interaction pattern of MAPKKKs with individual SSSRs was
detected. Among the EMMPRIN paralogs (EMMPRIN, NPTNβ and EMB),
DLK, TPL2 and ASK1 were commonly bound to them, and TAK1 was
strongly recruited to EMMPRIN. In contrast, RAGE paralogs (MCAM and
ALCAM) recruited DLK and TPL2 in a consistent manner, whereas ASK1
and MLK1 were additionally associated with MCAM (Figure 4, right
panel). Our previous work showed that RAGE has two MAPKKKs, TPL2
and ASK1, for its key signal onset [45].
Taking these findings together, we observed that TPL2 is the single
MAPKKK that is commonly located at the signal onset of the SSSRs. TPL2
Figure 3. Gene expression plots of the indicated genes (SSSRs) from cancer specimens were obtained from a publicly available website (http://gepia.cancer-pku.cn/). Data
are mean ± SD. * P < .01. ns: not significant.
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text of cancer, TPL2may give cancer cells increased abilities of cellular mo-
tility and survival, in light of the unusual role of the kinase in melanoma
and breast cancers' aggressiveness [10,9]. Regarding the SSSRs' signals
upon S100A8/A9 binding, on the basis of the central role of TPL2, another
binding MAPKKK may modify the downstream signals, and this may be
followed by altered cellular behaviors even in the same metastatic event.
Thus, the new finding of the potential usage of MAPKKKs in SSSRs may
help establish the details of the complex mechanisms of S100A8/A9-
SSSR-related cancer metastasis.
In addition to the above signal transductions of SSSRs that supply amet-
astatic driving force to cancer cells, certain proteins interacting with SSSRs
together on the cancer plasmamembranemay also affect cancermetastasis.
Tasdogan et al. recently reported a very interesting outcome that indicates a
critical role of lactate in cancer metastasis [46]. They demonstrated that an
enhanced lactate uptake through the major lactate transporter MCT1 in
melanoma cells promotes the cells' survival and metastasis in vivo. One of
the SSSRs, EMMPRIN, can bind to lactate transporters such as MCT1 and
MCT4 [47] and regulate their channel activity of lactate [48,49]. For5
example, EMMPRIN modulates lactate uptake via an interactive regulation
of MCT1 and MCT4 in many types of cancer cells that promotes cancer sur-
vival, drug resistance, dissemination and metastasis [49–53]. The disrup-
tion of the EMMPRIN-MCT1 interaction by immunomodulatory drugs
exerted efficient antitumor activity [54].
We thus hypothesized that one or more other SSSRs would also
bind with MCT(s) and regulate their activity, which may contribute
to cancer metastasis. To test this hypothesis, we examined the poten-
tial interaction between individual SSSRs and MCT1 or MCT4. Sur-
prisingly, our data (Figure 5, unpubl. data) showed that EMMPRIN
paralogs (NPTNα and NPTNβ) bind with both MCT1 and MCT4, as
does EMMPRIN. On the other hand, the RAGE and RAGE paralogs
ALCAM and MCAM can both bind with the single MCT1 in a similar
manner. These results suggest that all SSSRs can control the intracel-
lular lactate level via MCT, by which they contribute in part to cancer
metastasis. These data are part of our ongoing research, and we ex-
pect that further investigations will uncover the complex cross-talk
pathways with mutual signal transductions that lead to cancer
metastasis.
Table 1




Cancer species that highly
express SSSRs
References
MCAM Glioblastoma [31] Yawata et al., J. Neurooncol. (2019)
Hepatocellular
carcinoma
[32] Wang et al., Oncogene. (2015)
[33] Jiang et al., J. Exp. Clin. Cancer Res.
(2016)
Pancreatic cancer (−)
Melanoma [34] Pearl et al., J. Plast. Reconstr.
Aesthet. Surg. (2008)
[8] Ruma et al., Clin. Exp. Metastasis.
(2016)
[35] Sumardika et al., Oncol. Res. (2018)
[9] Chen et al., Cancer Lett. (2019)
ALCAM Breast cancer [36] Ihnen et al., Breast Cancer Res.
Treat. (2008)
Pancreatic cancer [37] Kahlert et al., Br. J. Cancer. (2009)
Prostate cancer [38] Kristiansen et al., Prostate. (2003)
[39] Hansen et al., Cancer Res. (2014)
EMMPRIN Hepatocellular
carcinoma
[40] Li et al., World J. Gastroenterol.
(2005)
Pancreatic cancer [41] Zhang et al., Int. J. Exp. Pathol.
(2016)
Melanoma [42] Kanekura et al., Int. J. Cancer.
(2002)
[5] Hibino et al., Cancer Res. (2013)
[43] Caudron et al., Exp. Dermatol.
(2016)
NPTN Pancreatic cancer (−)
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Strategies that prevent the signaling between S100A8/A9 and these re-
ceptors as described above may be useful for the suppression of ‘soil and
seed’-based lung-directed cancermetastasis. This idea spurred us to develop
a decoy and neutralizing antibody against extracellular S100A8/A9
(Figure 6). We then developed a therapeutic decoy [11] and S100A8/A9
antibody [12] and evaluated the suppressive effect of the antibody on
lung-directed cancer metastasis.
We prepared extracellular regions of these novel receptors and fused
them to human IgG2-Fc to extend the half-life expectancy [55] (novel
receptor-based decoys: exEMMPRIN-Fc, exNPTNβ-Fc, exMCAM-Fc and
exALCAM-Fc; classical receptor decoy: exRAGE-Fc). Because of the much
lower affinity of the IgG2 to Fc receptor compared to IgG1 [56], we used
IgG2 to avoid unexpected inflammatory events that might be caused by
the IgG-Fc receptor binding. Among the prepared decoys, exMCAM-Fc
showed the highest activity in suppressing metastasis. The exMCAM-Fc-in-
duced suppressive effect may be explained by the down-regulation of a se-
ries of metastatic soil-educating genes trigged by S100A8/A9 in the lungs.
To determinewhether cancer-mediated gene alterations in the lungs are
affected by exMCAM-Fc, we performed an RNA-seq-based comprehensive
analysis of gene expressions, using mouse lung. The results showed that
quite high numbers of genes were differentially expressed among the sev-
eral decoys compared to the control phosphate-buffered saline (PBS). We
therefore decided to focus on soluble factors such as cytokines, chemokines,
growth factors and secretory enzymes, since a metastatic soil feature is crit-
ically affected by certain inflammation-related soluble factors. Notably, the
genes that encoded soluble factors in reduction with exMCAM-Fc included
secretory proteinases, i.e., Mmp12, Mmp13 and Pla2g2d; an interleukin,
Il33; chemokines, Ccl19, Ccl1, Ccl2, Ccl5, Ccl8, Ccl12, Ccl21, Cxcl12 and
Cxcl5/6; and complement factor C5. Mmp12 andMmp13 are secretory ma-
trix metalloproteinases that contribute to cancer invasion via a matrix col-
lapse surrounding cancer cells, leading to cancer invasion [58,57]. In
addition to its proteinase activity, Mmp13 contributes to an increase in
the maturation of immune-suppressing Treg cells via the induction of
TGFβ [59].6
Il33 acts as a positive regulator of Treg cells at the functional side [60].
The group IID-secreted phospholipase A2 (Pla2g2d) is an immunosuppres-
sive phospholipase A2 that is secreted via the production of free fatty
acids from membrane lipids that are associated with chronic inflammation
and immune suppression [61]. An immune-suppressive environment trig-
gered byMmp13, Il33 and Pla2g2dmay thus be involved in raising themet-
astatic soil formation in the lungs. We also observed that the expressions of
many chemokines that are highly induced by chronic inflammation were
decreased by exMCAM-Fc treatment. All of the identified chemokines
may play an important role in a distant cancer's attraction to the lung
area in an additive or a synergistic manner. In particular, Ccl19, Ccl2,
Ccl21 and Cxcl12 attracted our attention.
The expression of the C-C chemokine receptor 7 (CCR7) that binds with
both Ccl19 and Ccl21 mediated themetastasis of breast cancer to the lymph
nodes in mice [62]. The Cxcl12 receptor C-X-C chemokine receptor 4
(CXCR4) promotes breast cancer cell metastasis to the lung [63]. Kitamura
et al. reported that a CCL2-induced chemokine cascade promotes the pul-
monary metastasis of breast cancer cells [64]. Complement C5 functions
as a strong chemokine to attract not only inflammatory cells but also cancer
cells [65].
Regarding the chemokines mentioned above, Eisenblaetter et al. re-
vealed an unusual role of the Ccl2 protein in the event of S100A8/A9-
mediated breast cancer metastasis toward the lung [66]. They succeeded
in the in vivo imaging of S100A8/A9 by using its antibody-based single
photon emission computed tomography (SPECT). By using this advanced
technique, Eisenblaetter et al. demonstrated that Ccl2 mediates the tumor
metastatic niche formation in the lung before breast cancer travels there.
Namely, breast cancer located at the mammary fat pad stimulates both
the induction of Ccl2 in the remote lung and an increase in the CCR2-
highCX3CR1low monocyte population at the same site, where Ccl2 readily
binds to its receptor CCR2 in the CCR2highCX3CR1low monocytes, resulting
in a significant level of S100A8/A9 secretion from the monocytes. Interest-
ingly, this process is associated with the increased presence of immunosup-
pressive Treg cells in mouse lung.
In the Eisenblaetter study, the anti-Ccl2 neutralizing antibodymarkedly
reduced the number of CCR2highCX3CR1low monocytes, S100A8/A9 secre-
tion, and lung-tropic breast cancer metastasis, indicating the presence of a
cancer-mediated positive feed-forward circuit of Ccl2-CCR2-S100A8/A9
in the lung for creating a pre-metastatic niche there. These results may pro-
vide one reason explaining the higher suppressive effect of the exMCAM-Fc
decoy on lung metastasis in the case of breast cancer cells, since exMCAM-
Fc remarkably reduced the Ccl2 expression in breast cancer-bearing mouse
lung. Taking these findings together, we speculate that the identified solu-
ble factorsmay all play a critical role inmetastatic soil formation in the lung
by modulating inflammation, immune activity, and cancer chemotactic at-
traction with invasiveness. In addition, a series of simultaneous
downregulations of all of the identified genes may reinforce the highest ef-
fect of exMCAM-Fc on the suppression of the lung-tropic metastasis of
breast cancer cells.
For the production of an optimal S100A8/A9 antibody, the preparation
of an optimal antigen is the most important step. To establish an inhibitory
antibody to S100A8/A9, we used our original S100A8/A9 recombinant
protein, which has been maintained as a 100% heterodimer with high pu-
rity, normal folding, and strong biological activity. After a multi-step
screening of antibodies for the desired inhibition, we identified one anti-
body (clone #45) that significantly suppresses lung-directed cancer metas-
tasis inmelanoma as well as breast cancer cells. The humanized antibody of
clone #45, abbreviated as chimeric-45, showed similar activity in vivo.
QuestionsAbout theBlockade Biologics Against the S100A8/A9-SSSRs
Axis (SSSR blockers)
An initial question is: what is the advantage of these SSSRs' blockers in
comparison to anti-CCL2 antibody in the suppressive function of lung-
tropic cancer metastasis? Bonapace et al. reported that it was difficult to
use an anti-CCL2 antibody as a single agent in cancer therapy [67]. Of
Figure 4. The interaction of the MAPK cascade upstream kinases (MAPKCUKs) with SSSRs. To examine certain interaction(s) between individual SSSRs andMAPKCUKs, we
constructed a series of expression vectors that express foreign genes of interest atmuch higher levels.We inserted the cDNAs of interest into pIDT-SMART (C-TSC) vector [81].
The prepared cDNAs were as follows: human cDNAs encoding SSSRs (EMMPRIN, NPTNβ, RAGE, MCAM and ALCAM) andMAPKCUKs (NAK, NIK, TAK1, DLK, TPL2, ASK1,
SPRK, MLK1, MEKK3, LZK and MLK4), which are designed for expression as C-terminal 3xHA-6His-tagged forms for SSSRs and as C-terminal 3xMyc-6His-tagged forms for
MAPKCUKs [9]. HEK292T cells were transiently transfected with the indicated combinations of the plasmid vectors using FuGENE-HD (Promega, Madison, WI). The co-im-
munoprecipitation andWestern blotting were performed as follows. Monoclonal anti-HA tag (clone HA-7) agarose (Sigma-Aldrich, St. Louis, MO) was used for the co-immu-
noprecipitation experiments. The tag-agarose beads weremixed with various cell extracts expressing an excess amount of foreign kinases (MAPKCUKs) and incubated for 3 h
at 4 °C. After the samples were incubated, bound proteins were pulled down by centrifugation and the precipitates were subjected to SDS-PAGE followed byWestern blotting
with mouse anti-Myc tag antibody (Cell Signaling Technology, Beverly, MA). Left panel: Schematic of the receptor-mediated signal ‘snowball.’ Right: The results of the inter-
actions examined.
N. Tomonobu et al. Translational Oncology 13 (2020) 100753course, the anti-CCL2 antibody highly reduced cancer metastasis in mice,
but an unexpected cessation of the treatment led to enhanced metastasis
and accelerated the death of the mice, since the interruption of the treat-
ment induced an influx ofmonocytes into the pre-metastatic lung and an in-
crease in IL-6 levels there, leading to a local enhancement of angiogenesis
in the lung [67]. Interestingly, this series of events was overcome by
using anti-IL-6 antibody in combination with the anti-CCL2 antibody.
On the other hand, we have shown that S100A8/A9 effectively induces
not only CCL2 [11] but also IL-6 [12]. The use of these blockers therefore
may be inhibitory to both CCL2 and IL-6 at the same time. Our ongoing re-
search includes functional comparisons of anti-CCL2 antibody and SSSRs'
blockers (especially anti-S100A8/A9 antibody and the exMCAM-Fc7
decoy) and evaluations of their therapeutic cessation for the prevention of
metastasis.
A logical next question is whether our SSSRs' blockers own suppressive
function is also exerted in other organ-tropic metastasis. To answer this
question, we need to learn more about the functional importance of
S100A8/A9 in organs such as the liver and brain (which are alsomajormet-
astatic destinations of cancers) for their metastasis profiles. We plan to
focus first on livermetastasis, since patients withmelanoma also frequently
suffer from liver metastasis [68,69]. In our metastatic mouse models,
i.e., an experimental forced model (melanoma injection by way of the tail
vein) and an autonomous model (making solid melanoma in the skin),
B16-BL6 mouse melanoma cells showed mainly lung-tropic metastasis
Figure 5.The interaction of SSSRswithMCT1 (gene name: SLC16A1) orMCT4 (gene name: SLC16A4).We inserted the cDNAs ofMCT1 andMCT4 into pIDT-SMART (C-TSC)
vector [81]; the cDNAs were designed for expression as C-terminal 3xFlag-6His-tagged forms. HEK292T cells were transiently transfectedwith the indicated combinations of
the plasmid vectors (individual SSSRs-3HA-6His plasmids andMCT1-3Flag-6His or MCT4-3Flag-6His plasmid) using FuGENE-HD. The co-immunoprecipitation andWestern
blotting were performed by a method similar to that described in Figure 3 except for the use of mouse anti-Flag tag antibody for Western blotting.
N. Tomonobu et al. Translational Oncology 13 (2020) 100753[11,12] but showed liver metastasis too, at a lower level than the lung me-
tastasis (unpubl. data). In this setting, we observed that S100A8/A9 was
also induced in the liver (unpubl. data).
In contrast, Saito et al. clearly revealed an interesting mechanism of
liver-tropic metastasis [70]. They used pancreatic cancer cells in which
complement component 5 alpha (C5a)—which is induced and secreted
from liver hepatocytes when pancreatic cancers appear in the pancreas in
a human (or in one or more organs other than the liver such as the spleen
in their model mouse of liver metastasis)—attracts pancreatic cancer
cells to the liver. Because C5a receptor (C5aR), an inflammatory relevant
chemokine receptor, is highly stabilized on the cell membrane in
podocalyxin-like 1 (PODXL1)-positive pancreatic cancer cells, the liver-
mediated C5a readily stimulates remote PODXL1-positive pancreatic can-
cer cells through a C5a-C5aR interaction, leading to their liver-tropic cancer
metastasis [70]. Interestingly, our RNA-seq data revealed that C5 mRNA-
encoded C5a is highly induced by S100A8/A9 [11].
Lee et al. proposed that in patients with pancreatic or colorectal
cancer, liver-mediated serum amyloid A1 (SAA1) and A2 (SAA2) play
crucial roles in the formation of a pro-metastatic niche in the liver
that recruits cancer cells to the liver [71]. In their report, in addition
to SAA1 and 2, S100A8/A9 was also markedly elevated in the liver of
mice bearing cancers that exhibited liver-tropic metastasis. Those find-
ings suggested that S100A8/A9 contributes in part to liver-tropic can-
cer metastasis. S100A8/A9 is also likely to be involved in brain-tropic
cancer metastasis. Liu et al. reported that S100A8/A9 was highly in-
duced in the CD11b+Gr1+ myeloid cells that accumulated in the
brain of mice bearing mouse breast cancer (4 T1) cells, and S100A8/
A9 thereby actively attracted 4 T1 cells [72].
Lastly, what are the precise clinical settings of cancer metastasis for
which the developed biologics are applicable? Our SSSRs' blockers exhib-
ited a great suppressive effect on the S100A8/A9-mediated lung-tropic can-
cer metastasis when we used them before cancer metastasis [12]. We thus
speculate that the developed biologics will be useful for cancer patients as
an effective anti-metastasis precaution after the surgical resection of solid
cancer, in combinationwith chemotherapeutic compounds. Further studies
may reveal additional uses of the developed biologics metastatic patients
with cancers at advanced stages.8
We expect that the newly developed antibody and decoys will eventu-
ally be of great help to the creation of antidotes to life-threatening cancer
metastasis—not only at the lung but also organs such as the liver and
brain—when combined with surgery and chemotherapeutic anticancer
drugs.
Conclusion
Researchers continue to observe that in the complex cancer meta-
static processes, novel receptors appear to act in cooperation with
each other with individual featured signal cascades at many specific
stages, not only on the cancer side (i.e., the EMT, adhesion, invasion,
migration and colonization with re-proliferation) but also on the met-
astatic organ side (the inflammatory immune-suppressive environ-
ment). The blockade biologics against the S100A8/A9-SSSRs axis
have shown significant preventive effects on cancer metastasis. In ad-
dition, S100A8/A9 heterodimer-mediated diseases are not restricted
to cancer metastasis; the S100A8/A9 protein contributes to many
types of inflammation-associated diseases (e.g., autoimmune diseases
including atopic dermatitis and arthritis, diabetes, and neurodegener-
ative diseases) [6,73–80]. We thus believe that our prior and ongoing
studies will help us gain a better understanding of the complexities
of cancer metastasis and other inflammatory diseases at the molecular
level, and our findings will contribute to the establishment of innova-
tive methods for preventing cancer metastasis and other inflammatory
diseases.
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